Overview

A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the bioequivalence of a newly developed ULTRACET extended-release (ER) tablet of tramadol hydrochloride and acetaminophen, to the current marketed ULTRACET ER tablet, in healthy participants under fasted condition.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Korea, Ltd., Korea

Treatments:

Acetaminophen
Tramadol